www.amphionplc.com
Amphion builds shareholder value in high growth companies in the medical and technology sectors, by using a focused, hands-on company building approach, based on decades of experience in both the US and UK.
Amphion has a significant shareholding in 8 Partner Companies developing proven technologies targeting substantial commercial marketplaces, each in excess of $1 billion. Each Partner Company is chosen with the goal of achieving an exit valuation in excess of $100 million.
Amphion pays directors’ fees with 273,976 shares
Amphion Innovations PLC (LSE: AMP), the developer of medical and technology businesses, has issued 273,976 shares in the company, representing 0.21 percent of the enlarged issued share capital, at 13.05 pence each, to certain board members in lieu of their directors' fees to June 2009.
Non-executive chairman Richard Mansell-Jones received 81,510 shares, and now holds 3.048 million shares, or 2.31 percent of the capital.
Non-executive director R James Maceleer has received a further 79.966 shares in Amphion and now has 22.444 million, or a 17.01 percent stake.
Non-executice director Anthony Henfrey has increased his holding by 62,500 shares to 1.128 million shares, or 0/86 percent.
Non-executive Gerard Moufflet has received 50,000 shares, or 0.04 percent of the capital.
Amphions’ investments include a 19.99% stake in liquid detection company Kromek, 15.3 percent in Firestar Software, 8.5 percent in Axcess International, 38.5 percent of Motif Biosciences, 50 percent in MSA Holdings B.S.C., a 24.4 percent stake in M2M Imaging Corp, 22 percent of Myconostica , 25 percent in Private Markets, 14.6 percent in WellGen and 100 percent of DataTern.
